Top

Published in:

01-10-2012 | Pathogenesis of Type 1 Diabetes (AG Ziegler, Section Editor)

Potential of Pluripotent Stem Cells for Diabetes Therapy

Author: Insa S. Schroeder

Published in: Current Diabetes Reports | Issue 5/2012

Abstract

Diabetes mellitus type 1 (T1DM) and type 2 (T2DM) are common diseases. To date, it is widely accepted that all forms of DM lead to the loss of beta cells. Therefore, to avoid the debilitating comorbidities when glycemic control cannot be fully achieved, some would argue that beta cell replacement is the only way to cure the disease. Due to organ donor shortage, other cell sources for beta cell replacement strategies have to be employed. Pluripotent stem cells, including embryonic stem (ES) and induced pluripotent stem (iPS) cells offer a valuable alternative to provide the necessary cells to substitute organ transplants but also to serve as a model to study the onset and progression of the disease, resulting in better treatment regimens. This review will summarize recent progress in the establishment of pluripotent stem cells, their differentiation into the pancreatic lineage with a focus on two-dimensional (2D) and three-dimensional (3D) differentiation settings, the special role of iPS cells in the analysis of genetic predispositions to diabetes, and techniques that help to move current approaches to clinical applications. Particular attention, however, is also given to the long-term challenges that have to be addressed before ES or iPS cell-based therapies will become a broadly accepted treatment option.

Grarup N, Overvad M, Sparso T, et al. The diabetogenic VPS13C/C2CD4A/C2CD4B rs7172432 variant impairs glucose-stimulated insulin response in 5722 non-diabetic Danish individuals. Diabetol. 2011;54:789–94.CrossRef

Ingelsson E, Langenberg C, Hivert MF, et al. Detailed physiologic characterization reveals diverse mechanisms for novel genetic loci regulating glucose and insulin metabolism in humans. Diabetes. 2010;59:1266–75.PubMedCrossRef

Manolopoulos VG, Ragia G, Tavridou A. Pharmacogenomics of oral antidiabetic medications: current data and pharmacoepigenomic perspective. Pharmacogenomics. 2011;12:1161–91.PubMedCrossRef

Power C, Rasko JE. Will cell reprogramming resolve the embryonic stem cell controversy? A narrative review. Ann Intern Med. 2011;155:114–21.PubMed

Evans MJ, Kaufman MH. Establishment in culture of pluripotential cells from mouse embryos. Nat. 1981;292:154–56.CrossRef

Thomson JA, Itskovitz-Eldor J, Shapiro SS, et al. Embryonic stem cell lines derived from human blastocysts. Sci. 1998;282:1145–47.CrossRef

D'Amour KA, Bang AG, Eliazer S, et al. Production of pancreatic hormone-expressing endocrine cells from human embryonic stem cells. Nat Biotechnol. 2006;24:1392–401.PubMedCrossRef

Kroon E, Martinson LA, Kadoya K, et al. Pancreatic endoderm derived from human embryonic stem cells generates glucose-responsive insulin-secreting cells in vivo. Nat Biotechnol. 2008;26:443–52.PubMedCrossRef

Sui J, Mehta M, Shi B, et al. Directed Differentiation of Embryonic Stem Cells Allows Exploration of Novel Transcription Factor Genes for Pancreas Development. Stem Cell Rev. 2012.

10.

Jiang J, Au M, Lu K, et al. Generation of insulin-producing islet-like clusters from human embryonic stem cells. Stem Cells. 2007;25:1940–53.PubMedCrossRef

11.

Phillips BW, Hentze H, Rust WL, et al. Directed differentiation of human embryonic stem cells into the pancreatic endocrine lineage. Stem Cells Dev. 2007;16:561–78.PubMedCrossRef

12.

Segev H, Fishman B, Ziskind A, et al. Differentiation of human embryonic stem cells into insulin-producing clusters. Stem Cells. 2004;22:265–74.PubMedCrossRef

13.

Zhang D, Jiang W, Liu M, et al. Highly efficient differentiation of human ES cells and iPS cells into mature pancreatic insulin–producing cells. Cell Res. 2009;19:429–38.PubMedCrossRef

14.

Nakanishi M, Hamazaki TS, Komazaki S, et al. Pancreatic tissue formation from murine embryonic stem cells in vitro. Differ. 2007;75:1–11.CrossRef

15.

Shi Y, Hou L, Tang F, et al. Inducing embryonic stem cells to differentiate into pancreatic beta cells by a novel 3-step approach with activin A and all–trans retinoic acid. Stem Cells. 2005;23:656–62.PubMedCrossRef

16.

Shim JH, Kim SE, Woo DH, et al. Directed differentiation of human embryonic stem cells towards a pancreatic cell fate. Diabetol. 2007;50:1228–38.CrossRef

17.

Cai J, Yu C, Liu Y, et al. Generation of homogeneous PDX1(+) pancreatic progenitors from human ES cell-derived endoderm cells. J Mol Cell Biol. 2010;2:50–60.PubMedCrossRef

18.

Rolletschek A, Kania G, Wobus AM. Generation of pancreatic insulin-producing cells from embryonic stem cells - 'proof of principle', but questions still unanswered. Diabetol. 2006;49:2541–45.CrossRef

19.

Vaca P, Berna G, Martin F, et al. Nicotinamide induces both proliferation and differentiation of embryonic stem cells into insulin-producing cells. Transplant Proc. 2003;35:2021–23.PubMedCrossRef

20.

Chen C, Chai J, Singh L, et al. Characterization of an in vitro differentiation assay for pancreatic-like cell development from murine embryonic stem cells:detailed gene expression analysis. Assay Drug Dev Technol. 2011;9:403–19.PubMedCrossRef

21.

Schroeder IS, Rolletschek A, Blyszczuk P, et al. Differentiation of mouse embryonic stem cells to insulin-producing cells. Nat Protoc. 2006;1:495–507.PubMedCrossRef

22.

Marenah L, McCluskey JT, Abdel-Wahab YH, et al. A stable analogue of glucose-dependent insulinotropic polypeptide, GIP(LysPAL16), enhances functional differentiation of mouse embryonic stem cells into cells expressing islet–specific genes and hormones. Biol Chem. 2006;387:941–7.PubMedCrossRef

23.

Tam PP, Loebel DA. Gene function in mouse embryogenesis:get set for gastrulation. Nat Rev Genet. 2007;8:368–81.PubMedCrossRef

24.

Takenaga M, Fukumoto M, Hori Y. Regulated Nodal signaling promotes differentiation of the definitive endoderm and mesoderm from ES cells. J Cell Sci. 2007;120:2078–90.PubMedCrossRef

25.

Sulzbacher S, Schroeder IS, Truong TT, et al. Activin A-induced differentiation of embryonic stem cells into endoderm and pancreatic progenitors-the influence of differentiation factors and culture conditions. Stem Cell Rev Rep. 2009;5:159–73.CrossRef

26.

Smith KN, Singh AM, Dalton S. Myc represses primitive endoderm differentiation in pluripotent stem cells. Cell Stem Cell. 2010;7:343–54.PubMedCrossRef

27.

Zhou J, Su P, Wang L, et al. mTOR supports long-term self-renewal and suppresses mesoderm and endoderm activities of human embryonic stem cells. Proc Natl Acad Sci USA. 2009;106:7840–5.PubMedCrossRef

28.

Manganelli G, Fico A, Masullo U, et al. Modulation of the pentose phosphate pathway induces endodermal differentiation in embryonic stem cells. PLoS One. 2012;7:e29321.PubMedCrossRef

29.

Blyszczuk P, Czyz J, Kania G, et al. Expression of Pax4 in embryonic stem cells promotes differentiation of nestin-positive progenitor and insulin-producing cells. Proc Natl Acad Sci U S A. 2003;100:998–1003.PubMedCrossRef

30.

Marchand M, Schroeder IS, Markossian S, et al. Mouse ES cells over-expressing the transcription factor NeuroD1 show increased differentiation towards endocrine lineages and insulin-expressing cells. Int J Dev Biol. 2009;53:569–78.PubMedCrossRef

31.

Johansson KA, Dursun U, Jordan N, et al. Temporal control of neurogenin3 activity in pancreas progenitors reveals competence windows for the generation of different endocrine cell types. Dev Cel. 2007;12:457–65.CrossRef

32.

Schwitzgebel VM, Scheel DW, Conners JR, et al. Expression of neurogenin3 reveals an islet cell precursor population in the pancreas. Dev. 2000;127:3533–42.

33.

Schroeder IS, Sulzbacher S, Nolden T, et al. (2011) Induction and selection of Sox17-expressing endoderm cells generated from murine embryonic stem cells. Cells Tissues Organs.

34.

Wang P, Rodriguez RT, Wang J, et al. Targeting SOX17 in human Embryonic stem cells creates unique strategies for isolating and analyzing developing endoderm. Cell Stem Cell. 2011;8:335–46.PubMedCrossRef

35.

Gadue P, Gouon-Evans V, Cheng X, et al. Generation of monoclonal antibodies specific for cell surface molecules expressed on early mouse endoderm. Stem Cells. 2009;27:2103–13.PubMedCrossRef

36.

Higuchi Y, Shiraki N, Yamane K, et al. Synthesized basement membranes direct the differentiation of mouse embryonic stem cells into pancreatic lineages. J Cell Sci. 2010;123:2733–42.PubMedCrossRef

37.

Shiraki N, Yoshida T, Araki K, et al. Guided differentiation of embryonic stem cells into Pdx1-expressing regional-specific definitive endoderm. Stem Cells. 2008;26:874–85.PubMedCrossRef

38.

Milewski WM, Temple KA, Wesselschmidt RL, et al. Generation of embryonic stem cells from mouse insulin I promoter-green fluorescent protein transgenic mice and characterization in a teratoma model. In Vitro Cell Dev Biol Anim. 2009;45:1–5.PubMedCrossRef

39.

Soria B, Roche E, Berna G, et al. Insulin-secreting cells derived from embryonic stem cells normalize glycemia in streptozotocin-induced diabetic mice. Diabetes. 2000;49:157–62.PubMedCrossRef

40.

Tsai ZY, Singh S, Yu SL, et al. Identification of microRNAs regulated by activin A in human embryonic stem cells. J Cell Biochem. 2010;109:93–102.PubMed

41.

•• Blum B, Hrvatin SS, Schuetz C, et al. Functional beta-cell maturation is marked by an increased glucose threshold and by expression of urocortin 3. Nat Biotechnol. 2012;30:261–4. This valuable and thoroughly conducted study gives insight into the identity of terminally differentiating pancreatic cells. Using urocortin3 may allow identification of factors leading to terminal maturation of stem cell progeny in vitro. PubMedCrossRef

42.

• Bergstrom R, Strom S, Holm F, et al. Xeno = free culture of human pluripotent stem cells. Methods Mol Biol. 2011;767:125–36. This study provides a thorough description of how hES cells can be cultured under conditions suitable for clinical applications. PubMedCrossRef

43.

Ilic D, Stephenson E, Wood V, et al. Derivation and feeder-free propagation of human embryonic stem cells under xeno-free conditions. Cytotherapy. 2012;14:122–8.PubMedCrossRef

44.

Rajala K, Lindroos B, Hussein SM, et al. A defined and xeno-free culture method enabling the establishment of clinical-grade human embryonic, induced pluripotent and adipose stem cells. PLoS One. 2010;5:e10246.PubMedCrossRef

45.

Lammert E, Cleaver O, Melton D. Induction of pancreatic differentiation by signals from blood vessels. Sci. 2001;294:564–7.CrossRef

46.

Lammert E, Cleaver O, Melton D. Role of endothelial cells in early pancreas and liver development. Mech Dev. 2003;120:59–64.PubMedCrossRef

47.

Otonkoski T, Banerjee M, Korsgren O, et al. Unique basement membrane structure of human pancreatic islets: implications for beta-cell growth and differentiation. Diabetes Obes Metab. 2008;10 Suppl 4:119–27.PubMedCrossRef

48.

Lee J, Cuddihy MJ, Kotov NA. Three-dimensional cell culture matrices:state of the art. Tissue Eng Part B Rev. 2008;14:61–86.PubMedCrossRef

49.

Linke K, Schanz J, Hansmann J, et al. Engineered liver-like tissue on a capillarized matrix for applied research. Tissue Eng. 2007;13:2699–707.PubMedCrossRef

50.

Mertsching H, Walles T, Hofmann M, et al. Engineering of a vascularized scaffold for artificial tissue and organ generation. Biomater. 2005;26:6610–17.CrossRef

51.

Mertsching H, Weimer M, Kersen S, et al. Human skin equivalent as an alternative to animal testing. GMS Krankenhhyg Interdiszip. 2008;3:Doc11.PubMed

52.

Jaramillo M, Banerjee I. Endothelial cell co-culture mediates maturation of human embryonic stem cell to pancreatic insulin producing cells in a directed differentiation approach. J Vis Exp. 2012.

53.

Mei Y, Hollister-Lock J, Bogatyrev SR, et al. A high throughput micro-array system of polymer surfaces for the manipulation of primary pancreatic islet cells. Biomater. 2010;31:8989–95.CrossRef

54.

• Cui X, Boland T. Human microvasculature fabrication using thermal inkjet printing technology. Biomaterials. 2009;30:6221–27. This paper reviews how easily technical devices can be used in a completely different setting to produce complex structures needed in regenerative medicine. CrossRef

55.

Cui X, Boland T, D'Lima DD, et al. Thermal inkjet printing in tissue engineering and regenerative medicine. Recent Pat Drug Deliv Formul. 2012.

56.

Daoud JT, Petropavlovskaia MS, Patapas JM, et al. Long-term in vitro human pancreatic islet culture using three-dimensional microfabricated scaffolds. Biomater. 2011;32:1536–42.CrossRef

57.

Banerjee M, Virtanen I, Palgi J, et al. Proliferation and plasticity of human beta cells on physiologically occurring laminin isoforms. Mol Cell Endocrinol. 2012;355:78–86.PubMedCrossRef

58.

Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126:663–76.PubMedCrossRef

59.

Aasen T, Izpisua Belmonte JC. Isolation and cultivation of human keratinocytes from skin or plucked hair for the generation of induced pluripotent stem cells. Nat Protoc. 2010;5:371–82.PubMedCrossRef

60.

Aoi T, Yae K, Nakagawa M, et al. Generation of pluripotent stem cells from adult mouse liver and stomach cells. Sci. 2008;321:699–702.CrossRef

61.

Utikal J, Maherali N, Kulalert W, et al. Sox2 is dispensable for the reprogramming of melanocytes and melanoma cells into induced pluripotent stem cells. J Cell Sci. 2009;122:3502–10.PubMedCrossRef

62.

Kim JB, Zaehres H, Wu G, et al. Pluripotent stem cells induced from adult neural stem cells by reprogramming with 2 factors. Nat. 2008;454:646–50.CrossRef

63.

Sun N, Panetta NJ, Gupta DM, et al. Feeder-free derivation of induced pluripotent stem cells from adult human adipose stem cells. Proc Natl Acad Sci U S A. 2009;106:15720–5.PubMedCrossRef

64.

Meng X, Neises A, Su RJ, et al. Efficient reprogramming of human cord blood CD34+ cells into induced pluripotent stem cells with OCT4 and SOX2 alone. Mol Ther. 2012;20:408–16.PubMedCrossRef

65.

Hanna J, Markoulaki S, Schorderet P, et al. Direct reprogramming of terminally differentiated mature B lymphocytes to pluripotency. Cell. 2008;133:250–64.PubMedCrossRef

66.

Seki T, Yuasa S, Fukuda K. Generation of induced pluripotent stem cells from a small amount of human peripheral blood using a combination of activated T cells and Sendai virus. Nat Protoc. 2012;7:718–28.PubMedCrossRef

67.

Stadtfeld M, Brennand K, Hochedlinger K. Reprogramming of pancreatic beta cells into induced pluripotent stem cells. Curr Biol. 2008;18:890–4.PubMedCrossRef

68.

Kim K, Doi A, Wen B, et al. Epigenetic memory in induced pluripotent stem cells. Nat. 2010;467:285–90.CrossRef

69.

Sullivan GJ, Bai Y, Fletcher J, et al. Induced pluripotent stem cells:epigenetic memories and practical implications. Mol Hum Reprod. 2010;16:880–5.PubMedCrossRef

70.

Bar-Nur O, Russ HA, Efrat S, et al. Epigenetic memory and preferential lineage-specific differentiation in induced pluripotent stem cells derived from human pancreatic islet beta cells. Cell Stem Cell. 2011;9:17–23.PubMedCrossRef

71.

Kim JB, Sebastiano V, Wu G, et al. Oct4-induced pluripotency in adult neural stem cells. Cell. 2009;136:411–19.PubMedCrossRef

72.

Sterneckert J, Hoing S, Scholer HR. Concise review: Oct4 and more:the reprogramming expressway. Stem Cells. 2012;30:15–21.PubMedCrossRef

73.

Lohle M, Hermann A, Glass H, et al. Differentiation efficiency of induced pluripotent stem cells depends on the number of reprogramming factors. Stem Cells. 2012;30:570–9.PubMedCrossRef

74.

Okita K, Nakagawa M, Hyenjong H, et al. Generation of mouse induced pluripotent stem cells without viral vectors. Sci. 2008;322:949–53.CrossRef

75.

Si-Tayeb K, Noto FK, Sepac A, et al. Generation of human induced pluripotent stem cells by simple transient transfection of plasmid DNA encoding reprogramming factors. BMC Dev Bio. 2010;10:81.CrossRef

76.

Redmer T, Diecke S, Grigoryan T, et al. E-cadherin is crucial for embryonic stem cell pluripotency and can replace OCT4 during somatic cell reprogramming. EMBO Rep. 2011;12:720–6.PubMedCrossRef

77.

Li W, Ding S. Small molecules that modulate embryonic stem cell fate and somatic cell reprogramming. Trends Pharmacol Sci. 2010;31:36–45.PubMedCrossRef

78.

Okita K, Ichisaka T, Yamanaka S. Generation of germline-competent induced pluripotent stem cells. Nat. 2007;448:313–17.CrossRef

79.

Fusaki N, Ban H, Nishiyama A, et al. Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome. Proc Jpn Acad Ser B Phys Biol Sci. 2009;85:348–62.PubMedCrossRef

80.

Kim D, Kim CH, Moon JI, et al. Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. Cell Stem Cell. 2009;4:472–6.PubMedCrossRef

81.

Zhou H, Wu S, Joo JY, et al. Generation of induced pluripotent stem cells using recombinant proteins. Cell Stem Cell. 2009;4:381–4.PubMedCrossRef

82.

Thier M, Munst B, Edenhofer F. Exploring refined conditions for reprogramming cells by recombinant Oct4 protein. Int J Dev Biol. 2010;54:1713–21.PubMedCrossRef

83.

Warren L, Manos PD, Ahfeldt T, et al. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell. 2010;7:618–30.PubMedCrossRef

84.

Miyoshi N, Ishii H, Nagano H, et al. Reprogramming of mouse and human cells to pluripotency using mature microRNAs. Cell Stem Cell. 2011;8:633–8.PubMedCrossRef

85.

Zhou Q, Melton DA. Extreme makeover: converting one cell into another. Cell Stem Cell. 2008;3:382–8.PubMedCrossRef

86.

Zhou Q, Brown J, Kanarek A, et al. In vivo reprogramming of adult pancreatic exocrine cells to beta-cells. Nat. 2008;455:627–32.CrossRef

87.

Alipio Z, Liao W, Roemer EJ, et al. Reversal of hyperglycemia in diabetic mouse models using induced-pluripotent stem (iPS)-derived pancreatic beta–like cells. Proc Natl Acad Sci U S A. 2010;107:13426–31.PubMedCrossRef

88.

Jeon K, Lim H, Kim JH, et al. Differentiation and transplantation of functional pancreatic beta cells generated from induced pluripotent stem cells derived from a type 1 diabetes mouse model. Stem Cells Dev. 2012.

89.

Zhu FF, Zhang PB, Zhang DH, et al. Generation of pancreatic insulin-producing cells from rhesus monkey induced pluripotent stem cells. Diabetol. 2011;54:2325–36.CrossRef

90.

Kunisada Y, Tsubooka-Yamazoe N, Shoji M, et al. Small molecules induce efficient differentiation into insulin-producing cells from human induced pluripotent stem cells. Stem Cell Res. 2012;8:274–84.PubMedCrossRef

91.

Ohmine S, Squillace KA, Hartjes KA, et al. Reprogrammed keratinocytes from elderly type 2 diabetes patients suppress senescence genes to acquire induced pluripotency. Aging. 2012;4:60–73. Albany, NY.PubMed

92.

Thatava T, Nelson TJ, Edukulla R, et al. Indolactam V/GLP-1-mediated differentiation of human iPS cells into glucose-responsive insulin-secreting progeny. Gene Ther. 2011;18:283–93.PubMedCrossRef

93.

Tateishi K, He J, Taranova O, et al. Generation of insulin-secreting islet–like clusters from human skin fibroblasts. J Biol Chem. 2008;283:31601–7.PubMedCrossRef

94.

McCarthy MI. Genomics, type 2 diabetes, and obesity. N Engl J Med. 2010;363:2339–50.PubMedCrossRef

95.

Maehr R, Chen S, Snitow M, et al. Generation of pluripotent stem cells from patients with type 1 diabetes. Proc Natl Acad Sci U S A. 2009;106:15768–73.PubMedCrossRef

96.

•• Zhao T, Zhang ZN, Rong Z, et al. Immunogenicity of induced pluripotent stem cells. Nature. 2011;474:212–15. This study demonstrates alarming results calling the superiority of iPS cells into question. CrossRef

97.

Blanchette JO, Langer SJ, Sahai S, et al. Use of integrin-linked kinase to extend function of encapsulated pancreatic tissue. Biomed Mater. 2010;5:061001.PubMedCrossRef

98.

Sakata N, Sumi S, Yoshimatsu G, et al. Encapsulated islets transplantation: past, present and future. World J Gastrointest Pathophysiol. 2012;3:19–26.PubMedCrossRef

99.

Kahan B, Magliocca J, Merriam F, et al. Elimination of tumorigenic stem cells from differentiated progeny and selection of definitive endoderm reveals a Pdx1+ foregut endoderm stem cell lineage. Stem Cell Res. 2011;6:143–57.PubMedCrossRef

Title: Potential of Pluripotent Stem Cells for Diabetes Therapy
Author: Insa S. Schroeder
Publication date: 01-10-2012
Publisher: Current Science Inc.
Published in: Current Diabetes Reports / Issue 5/2012
Print ISSN: 1534-4827
Electronic ISSN: 1539-0829
DOI: https://doi.org/10.1007/s11892-012-0292-5

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2012

Treg Vaccination with a Strong-Agonistic Insulin Mimetope

Erratum to: Understanding Pancreas Development for β-Cell Repair and Replacement Therapies

Transplantation of the Pancreas

Transition to Adult Care for Youth with Type 1 Diabetes

Influence of Type 1 Diabetes Genes on Disease Progression: Similarities and Differences Between Countries

Recovery of Endocrine Function After Islet and Pancreas Transplantation

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials